This trial is active, not recruiting.

Condition neuroblastoma
Treatment dfmo
Phase phase 2
Sponsor Giselle Sholler
Collaborator Beat NB Cancer Foundation
Start date March 2015
End date March 2018
Trial size 142 participants
Trial identifier NCT02395666, NMTRC003B


The purpose of this research study is to evaluate a new investigational drug to prevent reoccurrence of neuroblastoma that is in remission. This study drug is called DFMO. The objectives of this study will be to monitor for safety and look at efficacy of DFMO.

The safety of the proposed dosing regimen in this trial will be tested by an on-going risk/benefit assessment during the study. A patient benefiting from treatment, not progressing on therapy, and in the absence of any safety issues associated with DFMO may continue on treatment up to 27 cycles with the expectation that there will be an overall clinical benefit.

The procedures involved in this study include Medical history, Physical exam, Vital signs (blood pressure, pulse, temperature), Blood tests, Urine tests, MRI or CT scan of the tumor(s), meta-iodobenzylguanidine (MIBG) scans, and Bone marrow aspirations. All of these tests and procedures are considered standard of care for this population. Drug administration is also part of this protocol, including an investigational new drug called DFMO.

The proposed dosing regimen is an oral dose of DFMO tablets two times a day for each day while on study. There will be 27 cycles. Each cycle will be 28 days in length.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose prevention
Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
dfmo eflornithine HCl
Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.

Primary Outcomes

Number of participants with event free survival (EFS) during study.
time frame: 2 Years

Secondary Outcomes

Length of time that participants experience Overall Survival (OS)
time frame: 2 Years
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
time frame: 2 years
Number of participants with ODC single nucleotide polymorphisms.
time frame: 2 years
Polyamine Levels in Urine and blood
time frame: 2 years
Biomarker Analysis using antibody array analysis
time frame: 2 years
Circulating Tumor Cell Analysis
time frame: 2 years
Immunophenotyping of bone marrow samples
time frame: 2 years
Peak Plasma Concentration (Cmax)
time frame: 2 years
Area under the plasma concentration versus time curve (AUC)
time frame: 2 years
Time to reach Peak Plasma Concentration (Tmax)
time frame: 2 years

Eligibility Criteria

Male or female participants up to 21 years old.

Inclusion Criteria: - Age: 0-21 years at the time of diagnosis. - Diagnosis: histologic verification at either the time of original diagnosis or a previous relapse of high risk neuroblastoma. - Disease Status: Neuroblastoma that is in remission - First dose of study medication must be greater than 30 days from completion of cytotoxic and antibody therapy and less than 120 days from previous therapy - A negative serum or urine pregnancy test is required for female subjects of child bearing potential (onset of menses or ≥13 years of age). - Both male and female post-pubertal study subjects need to agree to use one of the more effective birth control methods during treatment and for six months after treatment is stopped. These methods include total abstinence (no sex), oral contraceptives ("the pill"), an intrauterine device (IUD), levonorgestrel implants (Norplant), or medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be used, contraceptive foam with a condom is recommended. - Absolute Neutrophil Count (ANC) > 500/μl and platelet count >50,000/μl - Organ Function Requirements: Subjects must have adequate liver function as defined by: - Aspartate Aminotransferase (AST) and Alanine transaminase (ALT) <10x upper limit of normal - Serum bilirubin must be ≤ 2.0 mg/dl - Serum creatinine based on age/gender - Informed Consent: All subjects and/or legal guardians must sign informed written consent. Assent, when appropriate, will be obtained according to institutional guidelines Exclusion Criteria: - Lansky score < 60% - Body Surface Area (BSA) (m2) of <0.25 - Investigational Drugs: Subjects who are currently receiving another investigational drug are excluded from participation. - Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are not eligible. Subjects must have fully recovered from the effects of prior chemotherapy (hematological and bone marrow suppression effects). - Infection: Subjects who have an uncontrolled infection are not eligible until the infection is judged to be well controlled in the opinion of the investigator. - Subjects who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study, or in whom compliance is likely to be suboptimal, should be excluded.

Additional Information

Official title A Phase II Preventative Trial of DFMO (Eflornithine HCl) as a Single Agent in Patients With High Risk Neuroblastoma in Remission
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Spectrum Health Hospitals.
Location data was received from the National Cancer Institute and was last updated in September 2016.